Treatment of thalassemia-induced osteoporosis with pamidronate
Phase 2
- Conditions
- Thalassemia.Beta thalassemiaD56.1
- Registration Number
- IRCT20211008052698N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Z-score < -2.5 in Bone Mineral Densitometry
Ferritin level>1000 mg/dl
More than 10 blood infusions or More than 100 cc/kg of blood infusion per year
Normal creatinine level
Normal blood counts
Exclusion Criteria
The positive history of bone-related disorders
Leukemia or Neoplastic disorders
Gastrointestinal disorders
Chronic inflammatory diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral densitometry. Timepoint: Baseline , Six month later. Method of measurement: Dual X-Ray absorptiometry.
- Secondary Outcome Measures
Name Time Method